Celldex Therapeutics, Inc. (CLDX) vs Maravai LifeSciences Holdings, Inc. (MRVI)
A side-by-side comparison of Celldex Therapeutics, Inc. and Maravai LifeSciences Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.10HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
MRVI
Maravai LifeSciences Holdings, Inc.
$7.96HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CLDX vs MRVI
growth of $100 · dividends reinvested · last 6yCLDX +62.9% (+8.5%/yr)MRVI -71.5% (-18.9%/yr)CLDX compounded faster over this window
Log scale — wide-divergence pair
CLDX MRVI
CLDX vs MRVI: by the numbers
- •MRVI is the larger company ($2.20B vs $2.07B market cap).
- •Both run net losses; MRVI's is the smaller (-37.07% vs -268385.71% net margin).
- •Both shrank revenue over the past five years; MRVI's decline was smaller (-17.68% vs -58.05% CAGR).
Metrics side by side
Valuation
| Metric | CLDX | MRVI |
|---|---|---|
| P/S ratio | 18477.97 | 10.53 |
| P/B ratio | 2.90 | 10.74 |
| EV / EBITDA | N/A | 15.22 |
Profitability
| Metric | CLDX | MRVI |
|---|---|---|
| Gross margin | 100.00% | 17.98% |
| Operating margin | -19160.00% | -3.63% |
| Net margin | -268385.71% | -37.07% |
| ROE | -42.07% | -37.82% |
| ROIC | -45.19% | 16.96% |
Growth (annualized)
| Metric | CLDX | MRVI |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | -17.68% |
| Total return CAGR (5Y) | -10.28% | -27.63% |
Frequently asked
- Which has grown faster, CLDX or MRVI?
- Neither grew: over the past five years both shrank revenue, with MRVI's decline the smaller — CLDX at a -58.05% CAGR versus MRVI at -17.68%.
- How have CLDX and MRVI total returns compared?
- Over the past 5 years, CLDX delivered -10.28% and MRVI delivered -27.63% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.